LATEST NEWS

05/08/13 Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting

04/24/13 Acucela Announces Initiation of Phase 2b/3 Clinical Trial of Emixustat Hcl (ACU-4429) in Subjects with Geographic Atrophy Associated with Dry Age-Related Macular Degeneration (AMD)



Welcome to Acucela

Acucela is leveraging promising science in visual cycle modulation to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide.

Innovative Approach

Acucela’s visual cycle modulators selectively target cells within the retina to protect visual acuity and have the potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD).

Executive Videos

At Acucela we believe that all people deserve the right to sight. Hear from our leadership team about how Acucela is poised to shape the future of eye disease therapies for people around the world.